Both Seres Therapeutics Inc. (NASDAQ:MCRB) and CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) are each other’s competitor in the Biotechnology industry. Thus the compare of their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Seres Therapeutics Inc.||5||6.35||N/A||-2.34||0.00|
|CollPlant Biotechnologies Ltd.||5||2.65||N/A||-0.80||0.00|
Table 1 showcases the top-line revenue, earnings per share and valuation of Seres Therapeutics Inc. and CollPlant Biotechnologies Ltd.
Table 2 represents Seres Therapeutics Inc. (NASDAQ:MCRB) and CollPlant Biotechnologies Ltd. (NASDAQ:CLGN)’s return on equity, net margins and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Seres Therapeutics Inc.||0.00%||235.9%||-81.2%|
|CollPlant Biotechnologies Ltd.||0.00%||0%||0%|
The next table highlights the shown recommendations and ratings for Seres Therapeutics Inc. and CollPlant Biotechnologies Ltd.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Seres Therapeutics Inc.||0||0||4||3.00|
|CollPlant Biotechnologies Ltd.||0||0||0||0.00|
Seres Therapeutics Inc.’s upside potential is 387.80% at a $14 average target price.
Institutional and Insider Ownership
Roughly 61.9% of Seres Therapeutics Inc. shares are owned by institutional investors while 23.69% of CollPlant Biotechnologies Ltd. are owned by institutional investors. Seres Therapeutics Inc.’s share owned by insiders are 0.4%. Comparatively, CollPlant Biotechnologies Ltd. has 19.13% of it’s share owned by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Seres Therapeutics Inc.||-9%||-7.46%||-55.32%||-55.46%||-62.76%||-39.6%|
|CollPlant Biotechnologies Ltd.||-12.5%||-30%||-36.3%||-27.34%||-42.53%||-16.67%|
For the past year Seres Therapeutics Inc. was more bearish than CollPlant Biotechnologies Ltd.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. Its product candidates in pre-clinical development comprise SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-155, an Ecobiotic microbiome therapeutic for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. and is headquartered in Ness Ziona, Israel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.